BioNTech SE (BVMF:B1NT34)

Brazil flag Brazil · Delayed Price · Currency is BRL
35.01
-0.99 (-2.75%)
At close: Feb 6, 2026
-20.79%
Market Cap139.64B -19.4%
Revenue (ttm)19.71B +3.7%
Net Income-3.57B
EPS-14.91
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume16
Average Volume800
Open35.01
Previous Close36.00
Day's Range35.01 - 35.01
52-Week Range30.80 - 44.60
Beta1.51
RSI45.71
Earnings DateMar 10, 2026

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 6,772
Stock Exchange Brazil Stock Exchange
Ticker Symbol B1NT34
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements